|| List of recent Acellular-related patents
| Stabilized bioactive peptides and methods of identification, synthesis, and use|
An intracellular selection system allows screening for peptide bioactivity and stability. Randomized recombinant peptides are screened for bioactivity in a tightly regulated expression system, preferably derived from the wild-type lac operon.
|Multi-layer vascular prosthesis|
A vascular prosthesis comprising a tubular support structure having an outer surface and an internal lumen therethrough, the support structure comprising a base material, which can comprise natural or synthetic materials, the internal lumen surface including an extracellular matrix (ecm) layer that includes at least one ecm material, wherein, when said vascular prosthesis is deployed proximate damaged cardiovascular tissue, the prosthesis induces modulated healing of the damaged tissue. In some embodiments, the support member outer surface also includes an ecm layer..
|Method to increase absorption and bioavailability of oral glutathione|
An improved method for delivery of glutathione, a major intracellular antioxidant, by oral administration of s-acetyl-glutathione (sag) is provided. The method is designed to raise the circulating blood levels of glutathione via the administration of an effective amount of sag in a delayed release composition..
|Gene delivery vehicles in the treatment of neurodegenerative diseases|
Currently no therapies that provide either protection or restoration of neuronal function for adult onset neurodegenerative diseases such as parkinson's disease exist. Many clinical efforts to provide such benefits by infusion of neurotropic factors have failed.
|Methods and compositions for the diagnosis of ovarian cancer|
A diagnostic reagent or device comprises at least one ligand capable of specifically complexing with, binding to, or quantitatively detecting or identifying the biomarker chloride intracellular channel protein 4 (clic4) or an isoform, pro-form, modified molecular form including posttranslational modification, or unique peptide fragment or nucleic acid fragment thereof. An alternative diagnostic reagent or device comprises ligand or ligands capable of specifically complexing with, binding to, or quantitatively detecting or identifying multiple tropomyosin biomarkers.
|Monoclonal antibody capable of binding integrin alpha 10 beta 1|
The present invention provides a monoclonal antibody or a fragment thereof binding to the extracellular i-domain of integrin alpha10beta1 and a hybridoma cell line deposited at the deutsche sammlung von microorganismen and zellkulturen gmbh under the accession number dsm acc2583. Furthermore, the present invention also provides a monoclonal antibody or a fragment thereof binding to the extracellular i-domain of integrin alpha10beta1 produced by the hybridoma cell line deposited.
|Non-naturally occurring t cell receptors|
A t cell receptor (tcr) having the property of binding to the gp100 ylepgpvta peptide-hla-a2 complex and comprising a tcr alpha variable domain and/or a tcr beta variable domain, characterized in that the domains are mutated relative to a tcr having the extracellular alpha and beta chain sequences seq id nos: 2 and that the tcr has a binding affinity for, and/or a binding half-life for, the ylepgpvta-hla-a2 complex at least double that of a reference tcr. Embodiments of the invention such as the use of such tcrs in adoptive therapy, and fusions of such tcrs with therapeutic agents are also described..
Provided herein are methods for the real-time monitoring of an intracellular event or response. In particular, the methods provided herein monitor the conversion of a pro-substrate to a substrate for a protein sensor as a result of an intracellular event or response..
|Unextracted tooth root canal filler and dental tissue regeneration method for unextracted tooth|
Disclosed is a root canal filler for non-extracted tooth which causes no internal resorption or external resorption in a tooth with complete root formation, shows no odontoclast, and contributes to the regeneration of a dental tissue in which odontoblasts are smoothly aligned on the dentin wall. After pulpectomy or enlargement/cleaning of an infected root canal, a root canal filler for non-extracted tooth, which comprises tooth pulp stem cells and an extracellular matrix, is inserted into the apical side of the root canal of the non-extracted tooth.
|Compositions, structures and methods for neural regeneration|
A nerve regeneration device comprising a support structure having an outer surface and a plurality of conduits extending therethrough, the support structure comprising a first extracellular matrix (ecm) material from a mammalian tissue source, the support structure outer layer including at least a first layer comprising a first ecm composition having at least a second ecm material from a mammalian tissue source. When the nerve regeneration device is deployed proximate damaged neural tissue, the device induces modulated healing of the damaged tissue..
|Method and system for treating biological tissue|
A tissue prosthesis comprising a support structure having at least one surface, the support structure comprising a base material, the support structure further including an extracellular matrix (ecm) composition having at least one ecm material from a mammalian tissue source. The tissue prosthesis induces modulated healing of damaged biological tissue when deployed proximate thereto..
|Ctla4 fusion proteins for the treatment of diabetes|
A method of treating, preventing, or delaying the progression of type 1 diabetes mellitus autoimmunity by administering an effective amount of a cytotoxic t-lymphocyte-associated antigen 4 (ctla4) molecule is provided herewith. The ctla4 molecule may be a fusion protein of a ctla4 extracellular region and an immunoglobulin, such as abatacept..
|Methods and compositions for treatment of retinal degeneration|
Disclosed herein are methods and compositions for treating retinal degeneration, such as occurs in retinitis pigmentosa and age-related macular degeneration, using descendents of marrow adherent stem cells that have been engineered to express an exogenous notch intracellular domain.. .
|Methods for production of proteins|
The current invention provides methods for producing a polypeptide as inclusion bodies in bacterial host cells. The present methods are carried out by forming a gene construct comprising the genetic sequence encoding a polypeptide operatively linked to that of an inclusion partner protein, such that host cells comprising the gene construct produce the polypeptide as intracellular inclusion bodies thereby facilitating rapid isolation and purification of recombinant proteins.
|Reinforced tissue graft|
A biocompatible tissue graft is provided. The tissue graft includes an extracellular matrix patch and a means for reinforcing the patch..
|Engineered cardiac tissues and methods of using them|
Engineered cardiac tissues are provided herein. The tissues include cardiomyocyte cells derived from a pluripotent cell, fibroblast cells and extracellular matrix components.
|Methods and compositions for the extracellular transport of biosynthetic hydrocarbons and other molecules|
The present disclosure identifies methods and compositions for modifying photoautotrophic organisms as hosts, such that the organisms efficiently convert carbon dioxide and light into hydrocarbons, e.g., n-alkanes and n-alkenes, wherein the n-alkanes are secreted into the culture medium via recombinantly expressed transporter proteins. In particular, the use of such organisms for the commercial production of n-alkanes and related molecules is contemplated..
|Process of afod and afcc and manufacturing and purification processes of proteins|
Manufacturing and purification processes of proteins, kh 1-through kh-52, and more kh proteins are being discovered in good healthy cells—named kh cells. Kh cells are good healthy cells in which the rna synthesizes good proteins that: 1) send signal to the damaged, sick, and bad cells that triggers that synthesis of good proteins that transform these cells to become good healthy cells; 2) send signal to the other currently undamaged cells to synthesis of good proteins to protect them from being damaged, infected and prone to dna and other cellular alterations; and 3) send signal to the body to produce new cells that are healthy and forbid them from being affected by intra- and extracellular damaging signals.
|Trapezium implant for thumb and method|
An implant for the trapezium of the thumb carpometacarpal (cmc) joint comprising an integral elastomeric member configured to include a body portion having a tapered neck, having extending from one end thereof an elongated, longitudinally extending tapered portion adapted to be embedded into a reamed out-channel in the thumb metacarpal bone. After implantation, in the preferred embodiment of the method according to the invention, a segment of a nearby tendon, for example, the apl or fcr tendons, may be wrapped around the tapered neck of the implant to secure it in position, thereby forming a reinforced structure to inhibit dislocation of the prosthesis.
|Method and system for treatment of cardiovascular disorders|
Methods for treating a cardiovascular disorder comprising concomitant administration of one or more extracellular matrix (ecm) based compositions directly to damaged or diseased cardiovascular tissue associated with the cardiovascular disorder, and provision of ventricular assistance. In a preferred embodiment, the ecm based compositions include an ecm material derived from a mammalian source..
|Enzyme and receptor modulation|
Covalent conjugates of an α,α-disubstituted glycine ester and a modulator of the activity of a target intracellular enzyme or receptor, wherein the ester group of the conjugate is hydrolysable by one or more intracellular carboxylesterase enzymes to the corresponding acid and the α,α-disubstituted glycine ester is conjugated to the modulator at a position remote from the binding interface between the inhibitor and the target enzyme or receptor pass into cells and the active acid hydrolysis product accumulates within the cells.. .
|Composition for the attachment of implants to collagen or other components of biological tissue|
The present invention relates to a novel composition comprising an implant, scaffold or construct bound to a biological or chemical moiety. The bound moiety has the ability to bind to a component of the extracellular matrix of biological tissue, allowing the implant to be bound to the biological tissue in a short period of time after implantation.
|Pepducin design and use|
Disclosed here is the rational design and use of potent and specific gpcr antagonist pepducins based on gpcr regions such as the third intracellular loop and adjacent regions.. .
|Novel microbial biocatalysts that enables use of cellodextrin as biofuel|
The present disclosure provides genetically engineered biocatalysts which enable intracellular assimilation of cellodextrin. The genetically engineered biocatalyst co-expresses a cellodextrin phosphorylase (cdp) gene and a cellobiose phosphorylase (cbp) gene.
|Method and system for treatment of biological tissue|
A composition for reconstruction, replacement or repair of damaged or diseased biological tissue comprising an extracellular matrix (ecm) composition that includes an ecm scaffold component derived from a mammalian source and at least one additional bioactive component selected from the group consisting of a statin and a chitin derivative.. .
|Pharmaceutical use of 2-(4-morpholinoaniline)-6-cyclohexyl aminopurine and pharmaceutically acceptable salt or derivative thereof|
The present invention provides a new use of 2-(4-morpholinoaniline)-6-cyclohexyl aminopurine and pharmaceutically acceptable salt or derivative thereof. The 2-(4-morpholinoaniline)-6-cyclohexyl aminopurine can inhibit the activated hepatic stellate cells from synthesizing and expressing collagens and other extracellular matrix proteins including mmps and timps, and so it can inhibit liver fibrosis.
|Good healthy cells found in proteins, their applications, and process of making a medium to harvest the cells|
Good healthy dragon, snake, different size double rings, lightning, square pixel, beaming rays, reconstruction background, facet, crater, yellow, leer cells were found in new proteins (among them 27 new ones and their sequences (under a different patent application) or in the existing discovered proteins and their applications. The process of making the medium derived from any source to harvest any cell—named kh cells—kh cells are good healthy cells in which the rna synthesizes good proteins that: 1—send signal to the damaged, sick, and bad cells that triggers that synthesis of good proteins that transform these cells to become good healthy cells.
|Surgical devices, kits, and related intra-operative methods for selecting breast implants|
Surgical tools, kits, and methods for breast implants are provided. One surgical tool is a rigid or semi-rigid form that matches the size and shape of a corresponding breast implant.
|Neurotrophic factor production promoting device|
A device to promote the production of neurotrophic factor without transplantation of cells or injection into the affected area is provided. The device contains a high frequency electromagnetic wave generating means generating a high frequency electromagnetic wave.
|Intracellular kinase inhibitors|
Intracellular kinase inhibitors and their therapeutic uses for patients with t cell malignancies, b cell malignancies, autoimmune disorders, and transplanted organs.. .
|Compositions and methods for macromolecular drug delivery|
The present invention features compositions and methods for delivering a therapeutic agent to the cytoplasm of a cell. We have developed, inter alia, a system in which two or more distinct moieties—at least one therapeutic moiety and at least one potentiating moiety—selectively target and specifically bind cell surface molecules that are then internalized to an intracellular, membrane-bound compartment, such as an endosome.
|Luminescent probes having a phenanthridinyl antenna, and methods of use|
A molecular probe for the luminescent detection of nucleotides (e.g., adenosine nucleotides) is presented. In certain embodiments, the probe can readily distinguish between the three adenosine nucleotides in buffered aqueous conditions at neutral ph, a need for the direct monitoring of enzymatic reactions converting atp to adp or amp.
|Means and methods for diagnosing and treating multiple sclerosis|
This invention relates to a peptide comprising or consisting of at least 8 consecutive amino acid residues of the sequence set forth in seq id no: 3, provided that said peptide does not consist of the sequence set forth in seq id no: 3, or a corresponding peptidomimetic, wherein said peptide or peptidomimetic binds to an anti-kir4.1 antibody comprised in a sample from a patient, said patient having multiple sclerosis or a predisposition therefor, wherein preferably (i) said at least 8 consecutive amino acid residues are a subsequence of an extracellular domain of kir4.1, said extracellular domain consisting of the sequence set forth in seq id no: 1 or 2; or (ii) said peptide comprises or consists of the sequence of seq id no: 1 or 2. The present invention furthermore relates to a method for diagnosing multiple sclerosis or a predisposition for multiple sclerosis in a subject, the method comprising determining the presence of an anti-kir4.1 antibody in a sample obtained from said subject, wherein the presence of an anti-kir4.1 antibody in said sample is indicative of multiple sclerosis or a predisposition for multiple sclerosis.
|Method for improving physical properties of antibody|
The present inventors discovered that physicochemical properties of a polypeptide can be improved by reducing the extracellular matrix-binding activity of the polypeptide.. .
|Method for detecting neurological disease associated with cognitive impairment by measuring epha4 extracellular domain|
A method for detecting a neurological disease associated with cognitive impairment, wherein the extracellular domain of epha4 is measured from a biological sample taken from a subject.. .
|Graft or tissue rinsing solution and method for rinsing said graft or tissue before revascularization|
Extracellular organ or tissue rinsing solution, comprising calcium, peg with a molecular weight of 35 000 at a concentration of at least 4 g/l, and potassium at a concentration of greater than or equal to 1, but less than 10 mmol/l.. .